Daiichi Sankyo Seeking Small Biotech Acquisitions In Europe
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo is scanning Europe for potential acquisitions that would help the Japanese company expand its market reach and enhance its product pipeline. Daiichi will focus on smaller biotechnology companies that have a strong oncology focus and a promising pipeline
You may also be interested in...
Daiichi Sankyo Expands MorphoSys Alliance To Include Antibodies For Infectious Disease
Japan's third-largest drug maker Daiichi Sankyo expanded its alliance with German biotech MorphoSys to include discovery and development of therapeutic antibodies for hospital-acquired infections. The earlier collaboration was focused solely on oncology
Daiichi Sankyo Expands MorphoSys Alliance To Include Antibodies For Infectious Disease
Japan's third-largest drug maker Daiichi Sankyo expanded its alliance with German biotech MorphoSys to include discovery and development of therapeutic antibodies for hospital-acquired infections. The earlier collaboration was focused solely on oncology
Astellas/Pfizer’s COX-2 Inhibitor Celecox Gains Additional Indications In Japan
Astellas Pharma and Pfizer Japan June 17 announced additional indications for their COX-2 inhibitor Celecox (celecoxib) in Japan for lumbago, scapulohumeral periarthritis, cervico-omo-brachial syndrome and tendinitis/tendosynovitis